Effects of omega-3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts
Effects of omega-3 fatty acid supplementation on vascular access thrombosis in polytetrafluorethylene grafts
复制标题
DOI：
10.1053/j.jrn.2006.07.009
复制
发表时间：
2007-03-01
影响因子：
3.2
通讯作者：
Leutholtz, Brian C.
中科院分区：
文献类型：
--
作者：
Bowden, Rodney G.;Wilson, Ronald L.;Leutholtz, Brian C.
目的：本研究的目的是探讨口服非处方 omega-3 (n-3) 脂肪酸补充剂对聚四氟乙烯 (PTFE) 移植物初次通畅的影响。设计：本研究采用三盲、排列分组、随机、安慰剂对照实验设计。背景：透析诊所的患者根据医生的诊断需要新的 PTFE 移植物。患者和其他参与者：长期接受治疗的患者对无法接受天然动静脉瘘的新放置的 PTFE 移植物进行血液透析。干预：将患者放入 n-3 脂肪酸组或对照组后前瞻性随访 8 个月，并监测初次通畅情况。主要结果变量：PTFE 移植物的初次通畅率。结果：n-3 脂肪酸组的平均 PTFE 移植物初次通畅率为 254.2 天（SEM = 51.8），而对照组组的平均 PTFE 移植物初次通畅率为 254.1 天（SEM = 34.6），表明各组之间的生存时间没有显着差异。结论：实验组和对照组的初次通畅率没有显着差异。 (C) 2007 年，国家肾脏基金会 (National Kidney Foundation, Inc.)
Objective: The purpose of this study was to investigate the effects of orally administered over-the-counter omega-3 (n-3) fatty acid supplements on primary patency of polytetrafluoroethylene (PTFE) grafts.Design: This study was conducted with a triple-blind, permuted-block, randomized, placebo-controlled experimental design.Setting: Dialysis clinics with patients who, in accordance with physician diagnosis, needed a new PTFE graft.Patients and Other Participants: Patients on long-term hemodialysis with newly placed PTFE grafts who were unable to receive a native arteriovenous fistula.Intervention: Patients were followed prospectively for 8 months after they had been placed into an n-3 fatty acid or control group and were monitored for primary patency.Main Outcome Variable: Primary patency of the PTFE graft.Results: The n-3 fatty acid group had a mean PTFE graft primary patency rate of 254.2 days (SEM = 51.8), and the control group had a mean PTFE graft primary patency rate of 254.1 days (SEM = 34.6), revealing no significant difference in survival time between groups.Conclusions: No significant differences in primary patency rates were noted in the experimental and control groups. (C) 2007 by the National Kidney Foundation, Inc.